These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26335104)

  • 1. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
    Duong le T; Leung AT; Langdahl B
    Calcif Tissue Int; 2016 Apr; 98(4):381-97. PubMed ID: 26335104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
    Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
    Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of odanacatib in the treatment of osteoporosis.
    Ng KW
    Clin Interv Aging; 2012; 7():235-47. PubMed ID: 22866001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
    Mukherjee K; Chattopadhyay N
    Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cathepsin K antagonists: preclinical and clinical data].
    Gamsjäger M; Resch H
    Wien Med Wochenschr; 2015 Feb; 165(3-4):65-70. PubMed ID: 25572547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
    Watanabe R; Okazaki R
    Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.
    Zhuo Y; Gauthier JY; Black WC; Percival MD; Duong LT
    Bone; 2014 Oct; 67():269-80. PubMed ID: 25038310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys.
    Pennypacker BL; Chen CM; Zheng H; Shih MS; Belfast M; Samadfam R; Duong LT
    J Bone Miner Res; 2014 Aug; 29(8):1847-58. PubMed ID: 24591096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate.
    Williams DS; McCracken PJ; Purcell M; Pickarski M; Mathers PD; Savitz AT; Szumiloski J; Jayakar RY; Somayajula S; Krause S; Brown K; Winkelmann CT; Scott BB; Cook L; Motzel SL; Hargreaves R; Evelhoch JL; Cabal A; Dardzinski BJ; Hangartner TN; Duong LT
    Bone; 2013 Oct; 56(2):489-96. PubMed ID: 23806798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
    Bone HG; McClung MR; Roux C; Recker RR; Eisman JA; Verbruggen N; Hustad CM; DaSilva C; Santora AC; Ince BA
    J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
    Bone HG; Dempster DW; Eisman JA; Greenspan SL; McClung MR; Nakamura T; Papapoulos S; Shih WJ; Rybak-Feiglin A; Santora AC; Verbruggen N; Leung AT; Lombardi A
    Osteoporos Int; 2015 Feb; 26(2):699-712. PubMed ID: 25432773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
    Lewiecki EM
    IDrugs; 2009 Dec; 12(12):799-809. PubMed ID: 19943223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.
    Leung P; Pickarski M; Zhuo Y; Masarachia PJ; Duong LT
    Bone; 2011 Oct; 49(4):623-35. PubMed ID: 21718816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cathepsin K for treatment of osteoporosis.
    Boonen S; Rosenberg E; Claessens F; Vanderschueren D; Papapoulos S
    Curr Osteoporos Rep; 2012 Mar; 10(1):73-9. PubMed ID: 22228398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
    Pirapaharan DC; Søe K; Panwar P; Madsen JS; Bergmann ML; Overgaard M; Brömme D; Delaisse JM
    Calcif Tissue Int; 2019 Jan; 104(1):92-101. PubMed ID: 30194476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.
    Duong LT; Clark S; Pickarski M; Giezek H; Cohn D; Massaad R; Stoch SA
    Osteoporos Int; 2022 Oct; 33(10):2165-2175. PubMed ID: 35711006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys.
    Masarachia PJ; Pennypacker BL; Pickarski M; Scott KR; Wesolowski GA; Smith SY; Samadfam R; Goetzmann JE; Scott BB; Kimmel DB; Duong LT
    J Bone Miner Res; 2012 Mar; 27(3):509-23. PubMed ID: 22113859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
    Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
    J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.
    Rizzoli R; Benhamou CL; Halse J; Miller PD; Reid IR; Rodríguez Portales JA; DaSilva C; Kroon R; Verbruggen N; Leung AT; Gurner D
    Osteoporos Int; 2016 Jun; 27(6):2099-107. PubMed ID: 26879200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.